Importantly, the triple drug combination was effective in FLT3-ITD+ leukemic cells independently from the presence of other fusion proteins, thereby providing a proof of concept that such a treatment may be a promising therapeutic strategy for this high-risk AML subset. Here, FLT3 is linked to acute myeloid leukemia.